Search Results - "онкологические пациенты"

1

Academic Journal

Thyroid status in patients with early stages of cancer of various localization ; Тиреоидный статус у пациентов на ранних стадиях рака различной локализации

Authors: V. A. Bandovkina, E. M. Frantsiyants, A. M. Salatova, M. A. Еngibaryan, V. L. Volkova, N. D. Cheryarina, В. А. Бандовкина, Е. М. Франциянц, А. М. Салатова, М. А. Енгибарян, В. Л. Волкова, Н. Д. Черярина

Contributors: this work was not funded., финансирование данной работы не проводилось.

Source: Research and Practical Medicine Journal; Том 11, № 2 (2024); 46-56 ; Research'n Practical Medicine Journal; Том 11, № 2 (2024); 46-56 ; 2410-1893 ; 10.17709/2410-1893-2024-11-2

Subject Terms: онкологические пациенты, thyroid stimulating hormone, thyroid hormones, cancer patients, тиреотропный гормон, тиреоидные гормоны

File Description: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/988/615; Sun Y, Xia PF, Korevaar TIM, Mustieles V, Zhang Y, Pan XF, Wang YX, Messerlian C. Relationship between Blood Trihalomethane Concentrations and Serum Thyroid Function Measures in U.S. Adults. Environ Sci Technol. 2021 Oct 19;55(20):14087–14094. https://doi.org/10.1021/acs.est.1c04008; Manolis AA, Manolis TA, Melita H, Manolis AS. Subclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call? Trends Cardiovasc Med. 2020 Feb;30(2):57–69. https://doi.org/10.1016/j.tcm.2019.02.011; Kalra S, Aggarwal S, Khandelwal D. Thyroid Dysfunction and Dysmetabolic Syndrome: The Need for Enhanced Thyrovigilance Strategies. Int J Endocrinol. 2021 Mar 29;2021:9641846. https://doi.org/10.1155/2021/9641846; Deng XY, Yi M, Li WG, Ye HY, Chen ZS, Zhang XD. The prevalence, hospitalization outcomes and risk factors of euthyroid sick syndrome in patients with diabetic ketosis/ketoacidosis. BMC Endocr Disord. 2023 Sep 12;23(1):195. https://doi.org/10.1186/s12902-023-01451-x; Krug N, Bercker S, Busch T, Friese S, Jahn N, Voelker MT. Non-thyroidal Illness Syndrome (NTIS) is no independent predictor for mortality in ICU patients. BMC Anesthesiol. 2023 Mar 31;23(1):103. https://doi.org/10.1186/s12902-023-01451-x; Hashemipour S, Shahsavari P, Kiani S, Badri M, Ghobadi A, Hadizadeh Khairkhahan SMR, et al. Wide spectrum of thyroid function tests in COVID-19: from Nonthyroidal Illness to isolated hyperthyroxinemia. Int J Endocrinol Metab. 2022;20(1):e120709. https://doi.org/10.5812/ijem.120709; Ashrafi S, Hatami H, Bidhendi-Yarandi R, Panahi MH. The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis. BMC Endocr Disord. 2024 Jan 2;24(1):5. https://doi.org/10.1186/s12902-023-01534-9; Cristinel Badiu D, Popescu GC, Zgura A, Mercan Stanciu A, Dodot MD, Mehedintu C, et al. A prospective observational study of 42 patients with COVID-19 infection and a history of hepatitis C virus infection and thyroid disease with follow-up thyroid function and autoantibody testing. Med Sci Monit. 2021;27:e935075. https://doi.org/10.12659/msm.935075; Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, et al. Cancer neuroscience: State of the field, emerging directions. Cell. 2023 Apr 13;186(8):1689–1707. https://doi.org/10.1016/j.cell.2023.02.002; Lan YL, Zou S, Wang W, Chen Q, Zhu Y. Progress in cancer neuroscience. MedComm. 2023 Nov 22;4(6):e431. https://doi.org/10.1002/mco2.431; Козлова М. Б., Франциянц Е. М., Светицкий П. В., Енгибарян М. А., Пустовая И. В., Черкес М. А., Исламова Е. Ф. Системный гормональный статус и состояние метаболизма гормонов у больных раком слизистой оболочки полости рта. Успехи современного естествознания. 2015;2:68–72. https://natural-sciences.ru/ru/article/view?id=34703; Jansen HI, Boelen A, Heijboer AC, Bruinstroop E, Fliers E. Hypothyroidism: The difficulty in attributing symptoms to their underlying cause. Front Endocrinol (Lausanne). 2023 Feb 6;14:1130661. https://doi.org/10.3389/fendo.2023.1130661; Франциянц Е. М., Бандовкина В. А., Каплиева И. В., Трепитаки Л. К., Черярина Н. Д., Димитриади С. Н., Пржедецкий Ю. В. Влияние роста перевивной меланомы В16/F10 на функционирование гипоталамо-гипофизарно-надпочечниковой и тиреоидной осей организма у самцов и самок мышей. Известия высших учебных заведений. Северо-Кавказский регион. Естественные науки. 2017;(3-2):118–124.; Бандовкина В. А., Франциянц Е. М., Кит О. И. Нейроэндокринные и метаболические аспекты патогенеза меланомы: экспериментально-клиническое исследование. М., 2023, 327 с.; Fliers E, Boelen A. An update on non-thyroidal illness syndrome. J Endocrinol Invest. 2021 Aug;44(8):1597–1607. https://doi.org/10.1007/s40618-020-01482-4; Франциянц Е. М., Бандовкина В. А., Ващенко Л. Н., Тодоров С. С., Черярина Н. Д., Салатова А. М., и др. Особенности синдрома эутиреоидного расстройства у больных раком молочной железы. Исследования и практика в медицине. 2023;10(3):21–31. https://doi.org/10.17709/2410-1893-2023-10-3-2; Gauthier BR, Sola-García A, Cáliz-Molina MÁ, Lorenzo PI, Cobo-Vuilleumier N, Capilla-González V, Martin-Montalvo A. Thyroid hormones in diabetes, cancer, and aging. Aging Cell. 2020 Nov;19(11):e13260. https://doi.org/10.1111/acel.13260; Kit OI, Bandovkina VA, Frantsiyants EM, Kaplieva IV, Surikova EI, Neskubina IV, et al. Disorders in connections of the hypothalamic-pituitarygonadal axis in rats with Guerin's carcinoma against the background of induced hypothyroidism. Cardiometry. 2023;(27):12–20. https://doi.org/10.18137/cardiometry.2023.27.1219; Франциянц Е. М., Бандовкина В. А., Каплиева И. В., Сурикова Е. И., Нескубина И. В., Погорелова Ю. А., и др. Изменение патофизиологии роста опухоли и функциональной активности гипоталамо-гипофизарно-тиреоидной оси у крыс обоего пола при развитии карциномы Герена на фоне гипотиреоза. Южно-Российский онкологический журнал. 2022;3(4):26–39. https://doi.org/10.37748/2686-9039-2022-3-4-3; Majos A, Sewerynek E, Grząsiak O, Ciesielski W, Hogendorf P, Hołyński J, et al. FT3 to FT4 Conversion Ratio May Be an Independent Prognostic Factor in Pancreatic Cancer Patients. Biomedicines. 2023 Dec 28;11(1):77. https://doi.org/10.3390/biomedicines11010077; Van den Berghe G. Non-Thyroidal Illness in the ICU: A Syndrome With Different Faces. Thyroid. 2014;24(10):1456–1465. https://doi.org/10.1089/thy.2014.0201; Cayrol F, Sterle HA, Montesinos MDM. Editorial: Thyroid hormone actions in cancer. Front Endocrinol (Lausanne). 2023 May 25;14:1219871. https://doi.org/10.3389/fendo.2023.1219871; Руяткина Л. А., Руяткин Д. С. Интегральный сердечно-сосудистый риск: метаболический синдром и дисфункция щитовидной железы. Сибирское медицинское обозрение. 2010;4(64):11–16.; Наниева А. Р., Хутугова И. А., Джиоев И. Г., Бузоева М. Р., Берёзова Д. Т. Функционально-морфологическое состояние почек при гипо- и гипертиреозе. Современные проблемы науки и образования. 2023;(5):94. https://doi.org/10.17513/spno.32939; Wang K, Zhang D, Cao G, Wang C, Wang L, Zhao R, et al. A Low Free T3 to Free T4 Ratio Is Associated with Sarcopenia in Euthyroid Patients with Type 2 Diabetes Mellitus. J Diabetes Res. 2022 Aug 17;2022:2305156. https://doi.org/10.1155/2022/2305156; Urrunaga-Pastor D, Guarnizo-Poma M, Moncada-Mapelli E, Aguirre LG, Lazaro-Alcantara H, Paico-Palacios S, et al. High free triiodothyronine and free-triiodothyronine-to-free-thyroxine ratio levels are associated with metabolic syndrome in a euthyroid population. Diabetes Metab Syndr. 2018;12(2):155–161. https://doi.org/10.1016/j.dsx.2017.12.003; Kong SH, Kim JH, Park YJ, Lee JH, Hong AR, Shin CS, Cho NH. Low free T3 to free T4 ratio was associated with low muscle mass and impaired physical performance in community-dwelling aged population. Osteoporos Int. 2020 Mar;31(3):525–531. https://doi.org/10.1007/s00198-019-05137-w; https://www.rpmj.ru/rpmj/article/view/988

Availability: https://www.rpmj.ru/rpmj/article/view/988
https://doi.org/10.17709/2410-1893-2024-11-2-4

View record from BASE

2

Academic Journal

ГЛАВHЫЕ ИТОГИ ИЗУЧЕHИЯ ОHКОЛОГИЧЕСКИХ АСПЕКТОВ ВИРУСHОГО ГЕПАТИТА В ЗА МИHУВШИЕ ТРИДЦАТЬ ЛЕТ

Authors: М. К. Мамедов, М. И. Михайлов

Source: Гепатология и гастроэнтерология, Vol 8, Iss 1, Pp 11-17 (2024)

Subject Terms: гепатит в, злокачественные опухоли, онкологические пациенты, Diseases of the digestive system. Gastroenterology, RC799-869

Relation: http://hepatogastro.grsmu.by/index.php/journalHandG/article/view/330; https://doaj.org/toc/2616-5546; https://doaj.org/toc/2708-5309; https://doaj.org/article/6d58a835566e493ab8c3febe5cbc7b8e

Availability: https://doi.org/10.25298/2616-5546-2024-8-1-11-17
https://doaj.org/article/6d58a835566e493ab8c3febe5cbc7b8e

View record from BASE

3

Academic Journal

Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials ; Тафалгин - отечественный инновационный тетрапептидный препарат для подкожного введения: обзор результатов клинических исследований I и II фаз

Authors: V. S. Kosorukov, G. R. Abuzarova, E. R. Zakharochkina, O. Yu. Gamzeleva, K. A. Yatsenko, В. С. Косоруков, Г. Р. Абузарова, Е. Р. Захарочкина, О. Ю. Гамзелева, К. А. Яценко

Contributors: The study was conducted with the support of the company PharmFirma “Sotex”., Исследование проведено при поддержке компании ЗАО «ФармФирма «Сотекс».

Source: Head and Neck Tumors (HNT); Том 12, № 2 (2022); 89-107 ; Опухоли головы и шеи; Том 12, № 2 (2022); 89-107 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2022-12-2

Subject Terms: пептиды, patients with cancer, tafalgin, peptides, онкологические пациенты, тафалгин

File Description: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/781/535; Van den Beuken-van Everdingen M.H.J., de Rijke J.M., Kessels A.G. et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18(9):1437-49. DOI:10.1093/annc/mdm056.; Pign T., Fernandez L., Ayasso S., et al. Impact of radiation oncology practice on pain: a cross-sectional survey. Int J Radiat Oncol Biol Phys 2004;60(4):1204-10. DOI:10.1016/j.ijrobp.2004.04.040.; Rietman J.S., Dijkstra P.U., Debreczeni R. et al. Impairments, disabilities and health related quality of life after treatment for breast cancer: a follow-up study 2.7 years after surgery. Disabil Rehabil 2004;26(2):78-84. DOI:10.1080/09638280310001629642.; Taylor K.O. Morbidity associated with axillary surgery for breast cancer. ANZ J Surg 2004;74(5):314-7. DOI:10.1111/j.1445-1433.2004.02992.x.; Bradley N., Davis L., Chow E. Symptom distress in patients attending an outpatient palliative radiotherapy clinic. J Pain Symptom Manage 2005;30(2):123—31. DOI:10.1016/j.jpainsymman.2005.02.015.; Di Maio M., Gridelli C., Gallo C. et al. Prevalence and management of pain in Italian patients with advanced nonsmall-cell lung cancer. Br J Cancer 2004;90(12):2288-96. DOI:10.1038/sj.bjc.6601810.; Hwang S.S., Chang V.T., Cogswell J. et al. Study of unmet needs in symptomatic veterans with advanced cancer: incidence, independent predictors and unmet needs outcome model. J Pain Symptom Manage 2004;28(5):421-32. DOI:10.1016/j.jpainsymman.2004.02.023.; Van den Beuken-van Everdingen M.H.J., Hochstenbach L.M.J., Joosten E.A.J. et al. Update on prevalence of pain in patients with cancer: systematic review and metaanalysis. J Pain Symptom Manage 2016;51(6):1070-90. DOI:10.1016/j.jpainsymman.2015.12.340.; Kroenke K., Theobald D., Wu J. et al. The association of depression and pain with health-related quality of life, disability, and health care use in cancer patients. J Pain Symptom Manage 2010;40(3):327-41. DOI:10.1016/j.jpainsymman.2009.12.023.; Deng D., Fu L., Zhao Y.X. et al. The relationship between cancer pain and quality of life in patients newly admitted to Wuhan Hospice Center of China. Am J Hosp Palliat Care 2012;29(1):53-9. DOI:10.1177/1049909111418636.; Porter L.S., Keefe F.J. Psychosocial issues in cancer pain. Curr Pain Headache Rep 2011;15(4):263-70. DOI:10.1007/s11916-011-0190-6.; Rief W., Bardwell W.A., Dimsdale J.E. et al. Long-term course of pain in breast cancer survivors: a 4-year longitudinal study. Breast Cancer Res Treat 2011;130(2):579-86. DOI:10.1007/s10549-011-1614-z.; Breivik H., Cherny N., Collett B. et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20(8): 1420-33. DOI:10.1093/annc/mdp001.; He Q.-H., Liu Q.-L., Li Z. et al, Impact of epidural analgesia on quality of life and pain in advanced cancer patients. Pain Manag Nurs 2015;16(3):307-13. DOI:10.1016/j.pmn.2014.08.003.; Ovayolu N., Ovayolu O., Serije S. et al. Pain and quality of life in Turkish cancer patients. Nurs Health Sci 2013;15(4):437-43. DOI:10.1111/nhs.12047.; Oliveira K.G., von Zeidler S.V., Podesta J. et al. Influence of pain severity on the quality of life in patients with head and neck cancer before antineoplastic therapy. BMC Cancer 2014;14:39. DOI:10.1186/1471-2407-14-39.; Bona L.G., Geleta D., Dulla D. et al. Ecomic burden of cancer on cancer patients treated at Hawassa University Comprehensive Specialized Hospital. Cancer Control. 2021;28:107327482110 09252. DOI:10.1177/10732748211009252.; Хронический болевой синдром (ХБС) у взрослых пациентов, нуждающихся в паллиативной медицинской помощи. Клинические рекомендации. 2016. Доступно по: https://b67c110e-c342-4f50-9588-194d66f0d842.filesusr.com/ugd/b488e5_3a5e5299af1645fda81a3cf6d5f2cdd6.pdf.; Cleary J.F. The pharmacologic management of cancer pain. J Palliat Med 2007;10(6):1369-94. DOI:10.1089/jpm.2007.9842.; Anekar A.A., Cascella M. WHO Analgesic Ladder, in StatPearls, Treasure Island (FL): StatPearls Publishing, 2022. Available at: http://www.ncbi.nlm.nih.gov/books/NBK554435/; WHO, WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018. Available at: https://www.who.int/publications/i/item/9789241550390.; Bennett M., Paice J.A., Wallace M. Pain and opioids in cancer care: benefits, risks, and alternatives. Am Soc Clin Oncol Educ Book 2017;37:705-13. DOI:10.1200/EDBK_180469.; Kosten T.R., George T.P. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 2002; 1(1):13-20. DOI:10.1151/spp021113.; Невзорова Д.В., Абузарова Г.Р., Полевиченко Е.В., Шершакова Л.В. Доступность опиоидных анальгетиков в лечении хронической боли в России. Современное состояние проблемы. Обзор. Pallium: Паллиативная и хосписная помощь 2020;2(7). Available at: https://www.elibrary.ru/item.asp?id=45812916&.; Mercadante S. Options for treating pain in cancer patients with dysphagia. Drugs 2017;77(6):629-35. DOI:10.1007/s40265-017-0710-8.; Storey P., Hill H.H., St. Louis R.H., Tarver E.E. Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage 1990;5(1):33-41. DOI:10.1016/S0885-3924(05)80007-7.; Bhattacharyya G.S. Oral systemic therapy: not all “win-win”. Indian J Med Paediatr Oncol 2010;31(1):1-3. DOI:10.4103/0971-5851.68844.; Letizia M., Shenk J., Jones T.D. Intermittent subcutaneous injections of pain medication: effectiveness, manageability, and satisfaction. Am J Hosp Palliat Care 1999;16(4):585-92. DOI:10.1177/104990919901600407.; Furst P., Lundstrom S., Klepstad P., Strang P. Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center. BMC Palliat Care 2020;19(1):172. DOI:10.1186/s12904-020-00681-3.; Crane R.A. Intermittent subcutaneous infusion of opioids in hospice home care: an effective, ecomical, manageable option. Am J Hosp Palliat Care 1994;11(1):8-12. DOI:10.1177/104990919401100103.; Harned M., Sloan P. Safety concerns with long-term opioid use. Expert Opin Drug Saf 2016;15(7):955-62. DOI:10.1080/14740338.2016.1177509.; Benyamin R., Trescot A.M., Datta S. et al. Opioid complications and side effects. Pain Physician 2008;11(2):105-20.; Daniell H.W. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3(5):377-84. DOI:10.1054/jpai.2002.126790.; Abs R., Verhelst J., Maeyaert J. et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocril Metab 2000;85(6):2215-22. DOI:10.1210/jcem.85.6.6615.; Daniell H.W. Opioid endocripathy in women consuming prescribed sustained-action opioids for control of nmalignant pain. J Pain 2008;9(1):28—36. DOI:10.1016/j.jpain.2007.08.005.; Walker J.M., Farney R.J., Rhondeau S.M. et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007;3(5):455-61.; Strassels S.A. Cognitive effects of opioids. Curr Pain Headache Rep 2008;12(1):32-6. DOI:10.1007/s11916-008-0007-4.; Boom M., Niesters M., Sarton E. et al. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des 2012;18(37):5994-6004. DOI:10.2174/138161212803582469.; Kata V., Vitch M.B., Jones M.R. et al. Opioid addiction, diversion, and abuse in chronic and cancer pain. Curr Opin Support Palliat Care 2018;12(2):124-30. DOI:10.1097/SPC.0000000000000333.; Bruera E., Paice J.A. Cancer pain management: safe and effective use of opioids. Am Soc Clin Oncol Educ Book 2015:e593-9. DOI:10.14694/EdBook_AM.2015.35.e593.; Mercadante S., Portey R.K. Breakthrough cancer pain: twenty-five years of study. Pain 2016;157(12):2657-63. DOI:10.1097/j.pain.0000000000000721.; Portey R.K., Payne D., Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81(1-2):129-34. DOI:10.1016/s0304-3959(99)00006-8.; Bruera E., Fainsinger R., MacEachern T., Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992;50(1):75-7. DOI:10.1016/0304-3959(92)90114-Q.; Fine P.G., Busch M.A. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998;16(3):179-83. DOI:10.1016/S0885-3924(98)00045-1.; Gomez-Batiste X., Madrid F., Moreno F. et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002;24(1):45-52. DOI:10.1016/s0885-3924(02)00421-9.; Davies A., Zeppetella G., Andersen S. et al. Multicentre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 2011;5(7):756-63. DOI:10.1016/j.ejpain.2010.12.004.; Taylor D.R., Webster L.R., Chun S.Y. et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 2007;8(3):281-8. DOI:10.1111/j.1526-4637.2007.00298.x.; Абузарова Г.Р., Лапина С.Е., Сарманаева Р.Р. «Прорывная боль» - новый термин, не новая проблема. Российский журнал боли 2017;54(3-4):8-17.; Pitt J.J. Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. Clin Biochem Rev 2009;30(1):19-34.; Ogu C.C., Maxa J.L. Drug interactions due to cytochrome P450. Proc Bayl Univ Med Cent 2000;13(4):421-3. DOI:10.1080/08998280.2000.11927719.; Smith H.S. Opioid metabolism. Mayo Clin Proc 2009;84(7):613-24.; Mercadante S., Intravaia G., Villari P. et al. Intraveus morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 2008;35(3):307-13. DOI:10.1016/j.jpainsymman.2007.04.018.; Mercadante S., Villari P., Ferrera P. et al. Safety and effectiveness of intraveus morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004;27(4):352-9. DOI:10.1016/j.jpainsymman.2003.09.006.; Jakobsen G., Engstrom M., Fayers P. et al. Sleep quality with WHO Step III opioid use for cancer pain. BMJ Support Palliat Care 2019;9(3):307-15. DOI:10.1136/bmjspcare-2017-001399.; Kamboj S.K., Tookman A., Jones L., Curran V.H. The effects of immediate-release morphine on cognitive functioning in patients receiving chronic opioid therapy in palliative care. Pain 2005;117(3):388-95. DOI:10.1016/j.pain.2005.06.022.; Okamoto Y., Tsuneto S., Tsugane M. et al. A retrospective chart review of opioid-induced nausea and somlence on commencement for cancer pain treatment. J Opioid Manag 2010;6(6):431-4. DOI:10.5055/jom.2010.0041.; Sugawara H., Uchida M., Suzuki S. et al. Analyses of respiratory depression associated with opioids in cancer patients based on the japanese adverse drug event report database. Biol Pharm Bull 2019;42(7):1185-91. DOI:10.1248/bpb.b19-00105.; https://ogsh.abvpress.ru/jour/article/view/781

Availability: https://ogsh.abvpress.ru/jour/article/view/781
https://doi.org/10.17650/2222-1468-2022-12-2-89-107

View record from BASE

4

Academic Journal

GENDER FEATURES OF CLINICAL-PSYCHOLOGICAL PHENOMENA IN CANCER PATIENTS ; ГЕНДЕРНЫЕ ОСОБЕННОСТИ ПРОЯВЛЕНИЯ КЛИНИКО-ПСИХОЛОГИЧЕСКИХ ФЕНОМЕНОВ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ ; ГЕНДЕРНІ ОСОБЛИВОСТІ ПРОЯВУ КЛІНІКО-ПСИХОЛОГІЧНИХ ФЕНОМЕНІВ У ОНКОЛОГІЧНИХ ПАЦІЄНТІВ

Authors: Krivonis, T. G., Zhulkevych, I. V.

Source: Achievements of Clinical and Experimental Medicine; No. 1 (2020); 115-119 ; Достижения клинической и экспериментальной медицины; № 1 (2020); 115-119 ; Здобутки клінічної і експериментальної медицини; № 1 (2020); 115-119 ; 2415-8836 ; 1811-2471 ; 10.11603/1811-2471.2020.v.i1

Subject Terms: clinical-psychological phenomena, cancer patients, gender, psychological help, psycho-oncology, клинико-психологические феномены, онкологические пациенты, гендер, психологическая помощь, психоонкология, клініко-психологічні феномени, онкологічні пацієнти, психологічна допомога, психоонкологія

File Description: application/pdf

Relation: https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/11078/10559

Availability: https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/11078
https://doi.org/10.11603/1811-2471.2020.v.i1.11078

View record from BASE

5

Academic Journal

Перспективы дистанционного наблюдения онкологических пациентов и удаленного доступа для обучения врачей ; Prospects for Remote Monitoring of Cancer Patients and Remote Access for Training Doctors

Authors: Старцев Владимир Юрьевич, ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России, Vladimir I. Startsev, FGBOU VO "Sankt-Peterburgskii gosudarstvennyi pediatricheskii meditsinskii universitet" Minzdrava Rossii

Source: Distance Learning: Current Issues; 125-129 ; Дистанционное обучение: актуальные вопросы; 125-129

Subject Terms: дистанционное обучение, телемедицина, диспансеризация, онкологические пациенты, коронавирусная пандемия

File Description: text/html

Relation: info:eu-repo/semantics/altIdentifier/isbn/978-5-907313-60-6; https://phsreda.com/e-articles/188/Action188-86008.pdf; Состояние онкологической помощи населению России в 2018 году / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. – М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. – 236 с.; Руководство по оказанию медицинской помощи онкологическим больным во время пандемии COVID-19: специальный отчет American Society of Clinical Oncology [Электронный ресурс]. – Режим доступа: https://www.asco.org/sites/new-www.asco.org/files/content-files/international-programs/documents/2020-ASCO-Guide-Cancer-COVID19-Russian.pdf (дата обращения: 12.07.2020).; What is COVID-19 and how will the pandemic affect my cancer care? URL: https://www.esmo.org/for-patients/patient-guides/cancer-care-during-the-covid-19-pandemic (дата обращения: 13.07.2020).; Wang H., Zhang L. Risk of COVID-19 for patients with cancer. The Lancet Oncology. 2020. – Vol. 21. – I. 4. – E181. DOI: https://doi.org/10.1016/S1470-2045(20)30149-2.; Institute of Medicine. Telemedicine: A Guide to Assessing Telecommunications for Health Care. Washington, DC: The National Academies Press; 1996. URL: https://books.google.ru/books?hl=en&lr=&id=Bu-bAgAAQBAJ&oi=fnd&pg=PP15&ots=OfdYtoNO6k&sig=pdZM1ATCeSCrDdgDVIp-ZCKqcNo&redir_esc=y#v=onepage&q&f=false (дата обращения: 13.07.2020).; Kruse C.S., Krowski N., Rodriguez B., et al. Telehealth and patient satisfaction: a systematic review and narrative analysis. BMJ Open 2017. – Vol. 7. – P. e016242. doi:10.1136/bmjopen-2017–016242.; Chen Y.Y., Guan B.S., Li Z.K., et al. Effect of telehealth intervention on breast cancer patients’ quality of life and psychological outcomes: a meta-analysis. J Telemed Telecare. Epub 2017 Jan 1. URL: https://doi.org/10.1177/1357633X16686777.; Worster B., Swartz K. Telemedicine and palliative care: an increasing role in supportive oncology. Curr Oncol Rep. 2017. – Vol. 19. – P. 37.; Фонд президентских грантов [Электронный ресурс]. – Режим доступа: https://xn--80afcdbalict6afooklqi5o.xn--p1ai/public/application/item?id=d0c063d0–0e13–4039–9d97–77da1edbe54c (дата обращения: 12.07.2020).; «Нетрика» и «ТехЛАБ» разработали «Онкопаспорт» — электронный регистр для мониторинга больных раком пациентов [Электронный ресурс]. – Режим доступа: https://netrika.ru/news/netrika-i-tehlab-razrabotali-onkopasport--elektronnyy-registr-dlya-monitoringa-bolnyh-rakom-pacientov (дата обращения: 12.07.2020).; «Нетрика» провела пилотное подключение системы «Онконет» к сервису N3.Health [Электронный ресурс]. – Режим доступа: https://netrika.ru/news/netrika-provela-pilotnoe-podklyuchenie-sistemy-onkonet-k-servisu-n3health (дата обращения: 12.07.2020).; Vitalscan [Электронный ресурс]. – Режим доступа: http://www.vitalscan.ru/index_ru.htm (дата обращения: 13.07.2020).; https://phsreda.com/files/Books/5fae43302b6f6.jpeg?req=86008; https://phsreda.com/article/86008/discussion_platform

Availability: https://phsreda.com/article/86008/discussion_platform
https://phsreda.com/files/Books/5fae43302b6f6.jpeg?req=86008
https://doi.org/10.31483/r-86008

View record from BASE

6

Academic Journal

Objective methods for assessing the severity of patients condition in a surgical intensive care unit ; Объективные методы оценки тяжести состояния пациентов в отделении реанимации онкохирургического профиля

Authors: F. A. Pchelintseva, M. V. Petrova, I. S. Shmyr, K. A. Mironov, E. V. Gameeva, Ф. А. Пчелинцева, М. В. Петрова, И. С. Шмыр, К. А. Миронов, Е. В. Гамеева

Source: Research and Practical Medicine Journal; Том 7, № 2 (2020); 116-128 ; Research'n Practical Medicine Journal; Том 7, № 2 (2020); 116-128 ; 2410-1893 ; 10.17709/2409-2231-2020-7-2

Subject Terms: метод экспертных оценок, oncological surgery, assessment of the severity of the condition, surgical risks, postoperative complications, cancer patients, expert evaluations, онкохируругия, оценка тяжести состояния, операционные риски, послеоперационные осложнения, онкологические пациенты

File Description: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/545/364; Azoulay E, Schellongowski P, Darmon M, Bauer PR, Benoit D, Depuydt P, et al. The Intensive Care Medicine research agenda on critically ill oncology and hematology patients. Intensive Care Med. 2017 Sep; 43(9): 1366–1382. https://doi.org/10.1007/s00134–017–4884-z; Феоктистов П.И., Карманов И. Е. Экстремальная операционная кровопотеря в онкохирургии: приговор пациенту или вызов персоналу? Клиническая практика. 2019; 10(3): 42–48. https://doi.org/10.17816/clinpract10342–48; Loh KP, Ramdass S, McHugh C, Mohile SG, Maggiore R. Assessing Frailty and Vulnerability in Older Adults with Cancer. Current Geriatrics Reports. 2017 Dec 1; 6(4): 231–238. https://doi.org/10.1007/s13670–017–0222–0; Shimabukuro-Vornhagen A, Böll B, Kochanek M, Azoulay É, von Bergwelt-Baildon MS. Critical care of patients with cancer. CA Cancer J Clin. 2016 Nov 12; 66(6): 496–517. https://doi.org/10.3322/caac.21351; Удалов Ю.Д., Гордиенко А.В., Самойлов А.С., Бахарев С.А. Прогнозирование и минимизация рисков фатальных исходов планового хирургического лечения онкологических больных с коморбидной соматической патологией. Медицина экстремальных ситуаций. 2018; 20(2): 136–145.; Александрович Ю.С., Гордеев В.И. Оценочные и прогностические шкалы в медицине критических состояний. 3 е изд., дополн. И исправл.— СПб.: ЭЛБИ-СПб, 2015.; Ghaffar S, Pearse RM, Gillies MA. ICU admission after surgery: who benefits? Curr Opin Crit Care. 2017 Oct; 23(5): 424–429. https://doi.org/10.1097/MCC.0000000000000448; Кашия Ш. Р. Особенности раннего послеоперационного периода при мультиорганных вмешательствах по поводу местнораспространенных злокачественных опухолей. Диссертация на соискание ученой степени кандидата медицинских наук. 2005. Доступно по: https://rusneb.ru/catalog/000199_000009_004065949/; Белялов Ф.И. Использование шкал прогноза в клинической медицине. Российский кардиологический журнал. 2016; 21(12): 23–27. https://doi.org/10.15829/1560–4071–2016–12–23–27; Darvall JN, Byrne T, Douglas N, Anstey JR. Intensive Care Practice in the Cancer Patient Population: Special Considerations and Challenges. Curr Anesthesiol Rep. 2018 Dec 1; 8(4): 439–447. https://doi.org/10.1007/s40140–018–0293–2; Белялов Ф.И. Прогнозирование заболеваний с помощью шкал. Комплексные проблемы сердечно-сосудистых заболеваний. 2018; 7(1): 84–93. https://doi.org/10.17802/2306–1278–2018–7-1–84–93; Karagoz S, TekdosSeker Y, Cukurova Z, Hergunsel O. The Effectiveness of Scoring Systems in the Prediction of Diagnosis-Based Mortality. TherApherDial. 2019 Oct; 23(5): 418–424. https://doi.org/10.1111/1744–9987.12780; Потанина О.К. Сравнение эффективности существующих прогностических моделей для оценки тяжести состояния реанима¬ццционных больных хирургического профиля. Диссертация на соискание ученой степени кандидата медицинских наук. 2012; 23 c.; Евтюков Г.М., Александрович Ю.С., Иванов Д.О. Оценка тяжести состояния больных, находящихся в критическом состоянии. Перспективы И Пути Развития Неотложной Педиатрии. 2006; 72–76.; Kingah P, Alzubaidi N, Yafawi JZD, Shehada E, Alshabani K, Soubani AO. Factors Associated with Mortality in Patients with a Solid Malignancy Admitted to the Intensive Care Unit — A Prospective Observational Study. J Crit Care Med (Targu Mures). 2018 Oct 1; 4(4): 137–142. https://doi.org/10.2478/jccm-2018–0019; Basile M, Press A, Adia AC, Wang JJ, Herman SW, Lester J, et al. Does Calculated Prognostic Estimation Lead to Different Outcomes Compared with Experience-Based Prognostication in the ICU? A Systematic Review. Crit Care Explor. 2019 Feb 1; 1(2): e0004. https://doi.org/10.1097/CCE.0000000000000004; Wijeysundera DN. Predicting outcomes: Is there utility in risk scores? Can J Anaesth. 2016 Feb; 63(2): 148–158. https://doi.org/10.1007/s12630–015–0537–2; Śmiechowicz J. Prognostic scoring systems for mortality in intensive care units — the APACHE model. Anaesthesiol Intensive Ther. 2015; 47(1): 87–88. https://doi.org/10.5603/AIT.2015.0009; Moreno RP, Nassar AP Jr. Is APACHE II a useful tool for clinical research? Rev Bras TerIntensiva. 2017 Sep; 29(3): 264–267. https://doi.org/10.5935/0103–507X.20170046; Le Gall J R, Loirat P, Alperovitch A, Glaser P, Granthil C, Mathieu D, et al. A simplified acute physiology score for ICU patients. Crit Care Med. 1984 Nov; 12(11): 975–977. https://doi.org/10.1097/00003246–198411000–00012; Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993 Dec 22; 270(24): 2957–2963. https://doi.org/10.1001/jama.270.24.2957; Jones HJ, de Cossart L. Risk scoring in surgical patients. Br J Surg. 1999 Feb; 86(2): 149–157. https://doi.org/10.1046/j.1365–2168.1999.01006.x; Moreno RP, Metnitz PGH, Almeida E, Jordan B, Bauer P, Campos RA, et al. SAPS 3— From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med. 2005 Oct; 31(10): 1345–1355. https://doi.org/10.1007/s00134–005–2763–5; Falcão ALE, Barros AG de A, Bezerra AAM, Ferreira NL, Logato CM, Silva FP, et al. The prognostic accuracy evaluation of SAPS 3, SOFA and APACHE II scores for mortality prediction in the surgical ICU: an external validation study and decision-making analysis. Ann Intensive Care. 2019 Jan 30; 9(1): 18. https://doi.org/10.1186/s13613–019–0488–9; Lemeshow S, Teres D, Klar J, Avrunin JS, Gehlbach SH, Rapoport J. Mortality Probability Models (MPM II) based on an international cohort of intensive care unit patients. JAMA. 1993 Nov 24; 270(20): 2478–2486.; Biskup E, Cai F, Vetter M, Marsch S. Oncological patients in the intensive care unit: prognosis, decision-making, therapies and end-of-life care. Swiss Med Wkly. 2017; 147: w14481. https://doi.org/10.4414/smw.2017.14481; Flavin K, Vasdev N, Ashead J, Lane T, Hanbury D, Nathan P, et al. Perioperative Considerations in Metastatic Renal Cell Carcinoma. Rev Urol. 2016; 18(3): 133–142. https://doi.org/10.3909/riu0697; Hong S, Wang S, Xu G, Liu J. Evaluation of the POSSUM, p POSSUM, o POSSUM, and APACHE II scoring systems in predicting postoperative mortality and morbidity in gastric cancer patients. Asian J Surg. 2017 Apr; 40(2): 89–94. https://doi.org/10.1016/j.asjsur.2015.07.004; González-Martínez S, Martín-Baranera M, Martí-Saurí I, Borrell-Grau N, Pueyo-Zurdo JM. Comparison of the risk prediction systems POSSUM and P POSSUM with the Surgical Risk Scale: A prospective cohort study of 721 patients. Int J Surg. 2016 May; 29: 19–24. https://doi.org/10.1016/j.ijsu.2016.03.005; Sekulic AD, Trpkovic SV, Pavlovic AP, Marinkovic OM, Ilic AN. Scoring Systems in Assessing Survival of Critically Ill ICU Patients. Med Sci Monit. 2015 Sep 4; 21: 2621–2629. https://doi.org/10.12659/MSM.894153; Потанина О.К., Дорфман А. Г., Швырёв С.Л., Зарубина Т.В., Петрова М.В. Опыт использования зарубежных нозонеспецифичных прогностических шкал у больных хирургического и онкологического профиля. Вестник Российского Научного Центра Рентгенорадиологии Минздрава России. 2011; (11–3): 74–85.; Fang Y, Wu C, Gu X, Li Z, Xiang J, Chen Z. Perioperative mortality and morbidity prediction using POSSUM, P POSSUM and APACHE II in Chinese gastric cancer patients: surgical method is a key independent factor affecting prognosis. Int J Clin Oncol. 2014 Feb; 19(1): 74–80. https://doi.org/10.1007/s10147–013–0525-x; Butterfield R, Stedman W, Herod R, Aneman A. Does adding ICU data to the POSSUM score improve the prediction of outcomes following surgery for upper gastrointestinal malignancies? Anaesth Intensive Care. 2015 Jul; 43(4): 490–496. https://doi.org/10.1177/0310057X1504300412; Kądziołka I, Świstek R, Borowska K, Tyszecki P, Serednicki W. Validation of APACHE II and SAPS II scales at the intensive care unit along with assessment of SOFA scale at the admission as an isolated risk of death predictor. Anaesthesiol Intensive Ther. 2019; 51(2): 107–111. https://doi.org/10.5114/ait.2019.86275; Орлов А.И. Экспертные оценки. Учебное пособие.М., 2002, 31 с. Доступно по: http://www.aup.ru/books/m154/; Данелян Т.Я. Формальные методы экспертных оценок. Экономика, статистика и экономика. Вестник УМО. 2015; (1): 183–187. https://doi.org/10.21686/2500–3925–2015–1-183–187; Dolan JG, Veazie PJ. Harnessing Expert Judgment to Support Clinical Decisions When the Evidence Base Is Weak. Med Decis Making. 2019; 39(1): 74–79. https://doi.org/10.1177/0272989X18810178; Денисова А.Л., Зайцев Е.В. Теория и практика экспертной оценки товаров и услуг. Учебное пособие. Тамбов: Изд-во Тамб. гос. техн. ун-та, 2002. 72 с.; https://www.rpmj.ru/rpmj/article/view/545

Availability: https://www.rpmj.ru/rpmj/article/view/545
https://doi.org/10.17709/2409-2231-2020-7-2-11

View record from BASE

7

Academic Journal

ПРЕИМУЩЕСТВА И НЕДОСТАТКИ ИСПОЛЬЗОВАНИЯ ПРОКАЛЬЦИТОНИНА В КЛИНИКЕ

Authors: Н. С. Багирова, И. Н. Петухова, З. В. Григорьевская, И. В. Терещенко, Н. В. Дмитриева

Source: Malignant tumours; Том 9, № 3s1 (2019); 32-42 ; Злокачественные опухоли; Том 9, № 3s1 (2019); 32-42 ; 2587-6813 ; 2224-5057

Subject Terms: фебрильная нейтропения, онкологические пациенты, сепсис

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/662/455; Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit.Care 2010;14: R15. DOI:10.1186/cc8872; de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, openlabel trial. Lancet Infect Dis 2016;16:819e27. http://dx.doi.org/10.1016/; Bonita Durnaś, Marzena Wątek, Tomasz- Wollny, Katarzyna Niemirowicz, Michał Marzec, Robert Bucki, Stanisław Góźdź. Utility of blood procalcitonin concentration in the management of cancer patients with infections. OncoTargets and Therapy 2016;9:469–475. http://dx.doi.org/10.2147/OTT.S95 600; Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49 (Suppl 1):S57 — S61. https://doi.org/10.2147/OTT.S95600; Hochreiter M., Kohler T., Schweiger A. et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care, 2009;13 (3): R83 doi:10.1186/cc7903.; Brunkhorst F.M., Forycki Z.F., Wagner J . Identif ication of immunoactivation of infectious origin by procalcitonin in body fluids [Abstract]. In: First International Symposium in Iena of Intensive Care Medicine, 1996. Clin. Intensive Care Suppl. 7/1.; Leon A., Lepouse C., Cousson J., et al. Procalcitonin in pleural effusion as a marker of septic response. [Abstract]. In: Fifth Vienna Shock Forum, 1995; GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; published online Aug http://dx.doi.org/10.1016/S1473–3099(17)30396–1; Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09. J Antimicrob Chemother 2014; 69: 234–40. doi:10.1093/jac/dkt301; Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med 2015; 373: 415–27. doi:10.1056/NEJMoa1 500 245; Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations; of COPD: a randomized, controlled trial comparing procalcitoninguidance with standard therapy. Chest. 2007 Jan;131 (1):9–19. DOI:10.1378/chest.06–1500; Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respirator y tract infections. Cochrane Database Syst Rev 2012;9: CD007 498. doi:10.1002/14651858.CD007498.pub3; Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, et al. Deescalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32–40. doi:10.1007/s00134‑013‑3077‑7; Schuetz P, Balk R, Briel M, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015; 53:583–592. doi:10.1515/cclm-2014–1015; Stojanovic I, Schneider JE, Wei L, et al. Economic evaluation of procalcitoninguided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective. Clin Chem Lab Med 2017; 55:561–570. doi:10.1515/cclm-2016–0349; Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10: CD007 498. doi:10.1002/14651858.CD007498.pub3; Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level metaanalysis. Lancet Infect Dis 2018; 18:95–107. doi:10.1016/S1473–3099 (17) 30 592–3.; Branche Angela, Neeser Olivia, Mueller Beat, Schuetz Philipp. Procalcitonin to guide antibiotic decision making. RESPIRATORY INFECTIONS: Edited by Michael S. Niederman: Curr Opin Infect Dis 2019; 32:130–135. DOI:10.1097/QCO.0000000000000522; Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol 2014; 175:464–472. doi:10.1016/j.ijcard.2014.06.022.; Schuetz P, Daniels LB, Kulkarni P, et al. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol 2016; 223:390–397. doi:10.1016/j.ijcard.2016.08.204; Llewelyn MJ, Fitzpatrick JM, Darwin E, et al. The antibiotic course has had its day. BMJ 2017; 358: j3418. doi:10.1136/bmj.j3418; Schuetz P, Mueller B. Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med 2014;40:141. doi:10.1007/s00134‑013‑3139‑x.; Carr JA. Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit. Journal of Intensive Care, 2015; 3: 36. doi:10.1186/s40560‑015‑0100‑9.; Schuetz P., Chiappa V., Briel et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine, 2011; 171 (15): 1322–1331. doi:10.1001/archinternmed.2011.318; Nobre V, Harbar th S, Graf JD, et al. Use of procalcitonin to shor ten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177:498–505. DOI:10.1164/rccm.200708-1238OC; Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin Monitoring SEpsis (MOSES) study. Crit Care Med 2017; 45:781–789. doi:10.1097/CCM.0 000 000 000; 321; van der Does Y, Limper M, Jie KE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre noninferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect 2018; 24:1282–1289. doi:10.1016/j.cmi.2018.05.011.; Schuetz P, Falsey AR. Procalcitonin in patients with fever: one approach does not fit all. Clin Microbiol Infect 2018; 24:1229–1230. doi:10.1016/j.cmi.2018.07.022; Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Doi Y, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med 2018; 379:236–249. doi:10.1056/NEJMoa1802670; Reynolds SC, Shorr AF, Muscedere J , Jiang X, Heyland DK. Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patients. Crit Care Med 2012; 40: 2781–87. DOI:10.1097/CCM.0b013e31 825b89cc; Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42: 1749–55. doi:10.1097/CCM.0 000 000 000 000 330; Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38: 1045–53. doi:10.1097/CCM.0b013e3181cc4824; Fontela PS, Quach C, Karim ME, et al. Determinants of antibiotic tailoring in pediatric intensive care: a national survey. Pediatr Crit Care Med 2017; 18: e395 — e405. doi:10.1097/PCC.0 000 000 000 001 238; Cremieux AC, Muller-Serieys C, Panhard X, et al. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments. Ant imicrob Agents Chemother 2003; 47: 2030–35. doi; 1128/AAC.47.6.2030–2035.2003; van Bijnen EME, Paget J, de Lange-de Klerk ESM, et al. Antibiotic exposure and other risk factors for antimicrobial resistance in nasal commensal Staphylococcus aureus: an ecological study in 8 European countries. PLoS One 2015; 10: e0 135 094. doi.org/10.1371/journal.pone.0 135 094; Dubos F., Korczowski B., Aygun D.A. et al. Distinguishing between bacterial and aseptic meningitis in children: European comparison of two clinical decision rules. Arch. Dis. Child., 2010; 95: 963–967. DOI:10.1136/adc.2010.186056; Leroy S., Gervaix A. Procalcitonin: a key marker in children with urinary tract infection. Adv. Urol., 2011;397 618 21 274 426. doi:10.1155/2011/397618; Galetto-Lacour A., Alcoba G., Posfay-Barbe K.M. et al. Elevated inflammatory markers combined with positive pneumococcal urinary antigen are a good predictor of pneumococcal communityacquired pneumonia in children. Pediatr. Infect. Dis J., 2013; 32 (11): 1175–1179. doi:10.1097/INF.0b013e31 829ba62a; Westwood ME, Ramaekers BLT, Whiting P, Tomini F, Joore MA, Armstrong N, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess 2015;19 (96). DOI:10.3310/hta19960; Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM (2019) The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patient s with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS ONE 14 (4): e0 214 222. https://doi.org /10.1371/journal.pone.0214222; Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and metaanalysis. Crit Care Med. 2018;46:691–698. doi:10.1097/CCM.0 000 000 000 002 928.; Patout M, Salaun M, B runel V, Bota S , Caul ie z B , Thiberville L. Diag¬nostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem. 2014;47 (18):263–267. doi:10.1016/j.clinbiochem.2014.09.002; Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis. 2006;43 (4):468–473. DOI:10.1086/505 394; Schuetz P.B., Mueller, A. Trampuz. Contamination from Bloodstream Infection due to Coagulase-Negative Staphylococci. Infection, 2007, 35 (5): 352–355. DOI 10.1007/s15010‑007‑7065‑0; Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest, 2010, 138: 121–129. DOI:10.1378/chest.09–2920; Hanine El Haddad, Anne-Marie Chaftari, Ray Hachem, Patrick Chaftari, and Issam I. Raad. Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer. Clinical Infectious Diseases® 2018;67 (6):971–7. DOI:10.1093/cid/ciy331; Matzaraki V, Alexandraki KI, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 2007;40:336–42. DOI:10.1016/j.clinbiochem.2006.10.027; Chaftari AM, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. PLOS One 2015; 10: e0 130 999. doi:10.1371/journal.pone.0130999; Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004; 10:1115–20. DOI:10.3748/wjg.v10.i8.1115; Ittner L, Born W, Rau B, Steinbach G, Fischer JA. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. Eur J Endocrinol 2002; 147:727–31. DOI:10.1530/eje.0.1 470 727; Avrillon V, Locatelli-Sanchez M, Folliet L, et al. Lung cancer may increase serum procalcitonin level. Infect Disord Drug Targets 2015; 15:57–63.; Shen H, Zheng S, Chen R, et al. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: a retrospective analysis of 509 cases. Medicine (Baltimore) 2017; 96: e7438. doi:10.1097/MD.0 000 000 000 007 438; Chen L, Zhang Y, Lin Y, et al. The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system. Clin Biochem 2017; 50:982–7. doi:10.1016/j.clinbiochem.2017.06.010; Yaegashi H, Izumi K, Kitagawa Y, et al. Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. Int J Urol 2014; 21:104–6. doi:10.1111/iju.12 178.; Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in nonneutropenic cancer patient s? Cancer 2012; 118:5823–9. doi:10.1002/cncr.27 602.; Gac AC, Parienti JJ, Chantepie S, et al. Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leuk Res. 2011;35 (10):1294–1296. doi:10.1016/j.leukres.2011; Carnino L, Betteto S, Loiacono M, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol. 2010;136 (4):611–615. doi:10.1007/s00432‑009‑0699‑9; Al Shuaibi M, Bahu RR, Chaftari AM, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis 2013; 56:943–50. doi:10.1093/cid/cis1029; Lucena CM, Rovira M, Gabarrus A, et al. The clinical value of biomarkers in respiratory complications in hematopoietic SCT. Bone Marrow Transplant 2017;52:415–22. doi:10.1038/bmt.2016.280; Debiane L, Hachem RY, Al Wohoush I, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. Crit Care Med 2014; 42:2500–7. doi:10.1097/CCM.0 000 000 000 000 526; Rast AC, Kutz A, Felder S, et al. Procalcitonin improves the Glasgow Prognostic Score for outcome prediction in emergency patients with cancer: a cohort study. Dis Markers 2015; 2015:795 801. doi:10.1155/2015/795 801; Ahn S, Lee YS, Lim KS, Lee JL. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 2013; 21:2303–8. doi:10.1007/s00 520‑013‑1787‑6; Lima SS, Nobre V, de Castro Romanelli RM, et al. Procalcitoninguided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol 2016; 95:1169–76. doi:10.1007/s00277‑016‑2639‑5; Haddad HE, Chaftari AM, Hachem R, et al. Procalcitonin guiding antimicrobial therapy duration in febrile cancer patients with documented infection or neutropenia. Sci Rep 2018; 8:1099. doi:10.1038/s41 598‑018‑19 616‑3; Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, BeaucheminM, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol 2017; 35:2082–2094. https://doi.org /10.1200/JCO.2016.71.7017; Miedema KGE, De Bont ESJM, Elferink RFMO et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2011; 19:1593–1600. https://doi.org/10.1007/s00 520‑010‑0987‑6; Hodgson-Viden H, Grundy PE, Robinson JL et al . Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr. 2005; 5:10. https://doi.org/10.1186/1471‑2431‑5‑10; Hilde T. van der Galiën & Erik A.H. Loeffen & Karin G.E. Miedema1& Wim J.E. Tissing. Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. Supportive Care in Cancer. 2018; 26:3819–3826. https://doi.org/10.1007/s00 520‑018‑4249‑3; https://www.malignanttumors.org/jour/article/view/662

Availability: https://www.malignanttumors.org/jour/article/view/662
https://doi.org/10.18027/2224-5057-2019-9-3s1-32-42

View record from BASE

8

Academic Journal

Quality Of Life In Cancer Patients During Treatment Process ; Качество жизни онкологических больных на этапах лечебного процесса ; Якість життя онкологічних хворих на етапах лікувального процесу

Authors: Мухаровська, Інна Романівна

Source: Psychiatry, Neurology and Medical Psychology; Том 4, № 1 (7) (2017); 91-95 ; Психиатрия, неврология и медицинская психология; Том 4, № 1 (7) (2017); 91-95 ; Психіатрія, неврологія та медична психологія; Том 4, № 1 (7) (2017); 91-95 ; 2411-166X ; 2312-5675

Subject Terms: cancer patients, quality of life, psychological help, psychooncology, онкологические пациенты, качество жизни, психологическая помощь, психоонкология, Онкологічні пацієнти, якість життя, психологічна допомога, психоонкологія